Response to statins in cardiovascular prevention: Hypo-responders' evaluation;Respuesta a las estatinas en prevención cardiovascular: Evaluación de los hiporrespondedores

Revista Argentina de Cardiologia

Volumn 82, Issue 1, 2014, Pages 34-41

  Masson, Walter ^a   Lobo, Martín ^a   Manente, Diego ^a   Vitagliano, Laura ^a   Rostán, María ^a   Siniawski, Daniel ^a   Huerin, Melina ^a   Giorgi, Mariano ^a  

^a SOCIEDAD ARGENTINA DE CARDIOLOGÍA   (Argentina)

Author keywords

Hypo responders; LDL Cholesterol; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; SEX DIFFERENCE;

EID: 84893053582     PISSN: 00347000     EISSN: 18503748     Source Type: Journal    
DOI: 10.7775/rac.es.v82.i1.2882     Document Type: Article

References (40)

1. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013 Jan 31;1:CD004816.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22. http://doi.org/dv5h77
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. http://doi.org/d3zs8f
5. Smith MEB, Lee NJ, Haney E, Carson S. Drug class review: HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin: Final report update 5 [Internet]. Portland (OR): Oregon Health & Science University, 2009 Nov. http://www.ncbi.nlm.nih.gov/books/NBK47273. Consultado el 01/06/2013.
6. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;93:152-60. http://doi.org/fjv726
7. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7. http://doi.org/dbc3rn
8. Mangravite LM, Wilke RA, Zhang J, Krauss RM. Pharmacogenomics of statin response. Curr Opin Mol Ther 2008;10:555-61.
9. Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, Durrington PN. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res 2012;53:1000-11. http://doi.org/pjr
10. Bai JP. Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics. Drug Metab Pharmacokinet 2010;25:62-71. http://doi.org/fmbz64
11. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA 2009;106:14728-33. http://doi.org/cr4zw9
12. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 2011;6:e25482. http://doi.org/dkh6p5
13. Vaquero MP, Sanchez Muniz FJ, Jimenez Redondo S, Prats Olivan P, Higueras FJ, Bastida S. Major diet-drug interactions affecting the kinetic characteristics and hypolipidaemic properties of statins. Nutr Hosp 2010;25:193-206.
14. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008;48:653-83. http://doi.org/b2wwk7
15. Ziajka PE, Reis M, Kreul S, King H. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. Am J Cardiol 2004;93:779-80. http://doi.org/bwdx9t
16. Thompson G, O'Neill F, Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 2002;23:200-6. http://doi.org/fscgx5
17. Senaratne J, Griffiths J, Macdonald K, Senaratne MP. Evidence for cholesterol hyperabsorbers and hyperproducers based on comparative low-density lipoprotein reductions achieved by ezetimibe versus statins. J Cardiopulm Rehabil Prev 2012;32:250-4. http://doi.org/pjs
18. Consenso de Prevención Cardiovascular. Sociedad Argentina de Cardiología-Área de Normatizaciones y Consensos. Rev Argent Cardiol 2012;80(Supl 2):1-126.
19. Adult Treatment Panel III, Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001;285:2486-97. http://doi.org/d39ksv
20. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701. http://doi.org/m5d
21. Tattersall MC, Gangnon RE, Karmali KN, Cullen MW, Stein JH, Keevil JR. Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 national health and nutrition examination surveys. PLoS One 2013;8:e59309. http://doi.org/pjt
22. Navarro-Vidal B, Banegas JR, León-Muñoz LM, Rodríguez-Artalejo F, Graciani A. Achievement of cardiometabolic goals among diabetic patients in Spain. A nationwide population-based study. PLoS One 2013;8:e61549. http://doi.org/pjv
23. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97. http://doi.org/fgvdqn
24. Pedan A, Varasteh L, Schneeweiss S. Analysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristics. J Manag Care Pharm 2007;13:487-96.
25. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 2012;5:257-64. http://doi.org/pjw
26. Lally S, Tan CY, Owens D, Tomkin GH. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: The role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 2006;49:1008-16. http://doi.org/bd3vhz
27. Tomkin GH. The intestine as a regulator of cholesterol homeostasis in diabetes. Atheroscler Suppl 2008;9:27-32. http://doi.org/br4z4t
28. Gylling H, Miettinen TA. Cholesterol absorption and lipoprotein metabolism in type II diabetes mellitus with and without coronary artery disease. Atherosclerosis 1996;126:325-32. http://doi.org/bjsb3s
29. Matthan NR, Pencina M, Larocque JM, Jacques PF, D'Agostino RB, Schaefer EJ, et al. Alterations in cholesterol absorption and synthesis characterize Framingham offspring study participants with coronary heart disease. J Lipid Res 2009;50:1927-35. http://doi.org/df3rv5
30. Simonen P, Gylling H, Miettinen TA. The validity of serum squalene and non-cholesterol sterols as surrogate markers of cholesterol synthesis and absorption in type 2 diabetes. Atherosclerosis 2008;197:883-8. http://doi.org/d6gwqb
31. Abramson BL, Benlian P, Hanson ME, Lin J, Shah A, Tershakovec AM. Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients. Lipids Health Dis 2011;10:146. http://doi.org/bm9pfn
32. Shigematsu E, Yamakawa T, Taguri M, Morita S, Tokui M, Miyamoto K, et al. Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes. J Atheroscler Thromb 2012;19:846-53. http://doi.org/pjx
33. Shear CL, Franklin FA, Stinnett S, Hurley DP, Bradford RH, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992;85:1293-303. http://doi.org/pjz
34. Cone C, Murata G, Myers O. Demographic determinants of response to statin medications. Am J Health Syst Pharm 2011;68:511-7. http://doi.org/dhgvd9
35. Naoumova RP, Marais AD, Mountney J, Firth JC, Rendell NB, Taylor GW, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996;119:203-13. http://doi.org/dftqdt
36. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993;87(4 Suppl):III35-44.
37. Farnier M, Averna M, Missault L, Vaverkova H, Viigimaa M, Massaad R, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy. The IN-CROSS study. Int J Clin Pract 2009;63:534-5. http://doi.org/bjxhs2
38. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411-6. http://doi.org/ddz6m2
39. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82. http://doi.org/b3v5gj
40. Miettinen TA, Gylling H, Strandberg T, Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 1998;316:1127-30. http://doi.org/dk2c27